CORE--PHOTOSENSITIZER EVALUATION

核心--光敏剂评价

基本信息

  • 批准号:
    6300346
  • 负责人:
  • 金额:
    $ 17.97万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2000
  • 资助国家:
    美国
  • 起止时间:
    2000-05-01 至 2001-04-30
  • 项目状态:
    已结题

项目摘要

One emphasis of this program project is to develop new phthalocyanine (Pc) photosensitizers (PS) with better antitumor properties for PDT. The purpose of the 'photosensitizer evaluation core' is to establish basic in vitro and in vivo data on the Pc PS synthesized in Project 1. For this purpose, the core will provide information generated in standardized analysis. Each newly synthesized PS will be assessed in parallel with Pc 4, and the photodynamic efficacy of the compound will be rated in the standardized test system as 'inferior', 'equal' or 'superior' to Pc 4. The results will be communicated to the program investigators. The choice for ranking of newly synthesized compounds in relation to Pc 4 is made because a) this was the lead compound among the first 10 synthesized, and b) other projects have considerable experience and preliminary data with this compound. This core will also generate more detailed information on selected promising PS. For this, the decision will be made by the investigators of Projects 1-3. The Director of this core Project is also a co-investigator of Project 3, and therefore will also participate in decisions, experimental designs, and data interpretation for these studies. The core will perform the following six functions: 1. We will determine the partitioning of newly synthesized PS between n-octanol vs. saline. 2. We will conduct initial in vitro evaluation of PS. 3. We will define initial PDT responses of PS. 4. We will determine distribution of PS in plasma, tumor and other tissues in vivo. 5. We will determine systemic toxicity and cutaneous photosensitivity responses of PS, and 6. We will study detailed PDT effects of selected PS. The priority for testing each PS will vary with the type of structure. This 'decision network' is described in the program narrative.
本项目的重点之一是开发新型酞菁

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

MALCOLM E KENNEY其他文献

MALCOLM E KENNEY的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('MALCOLM E KENNEY', 18)}}的其他基金

DRUGS FOR PHOTODYNAMIC THERAPY
光动力治疗药物
  • 批准号:
    7355170
  • 财政年份:
    2006
  • 资助金额:
    $ 17.97万
  • 项目类别:
DRUGS FOR PHOTODYNAMIC THERAPY
光动力治疗药物
  • 批准号:
    7180085
  • 财政年份:
    2005
  • 资助金额:
    $ 17.97万
  • 项目类别:
DRUGS FOR PHOTODYNAMIC THERAPY
光动力治疗药物
  • 批准号:
    6977056
  • 财政年份:
    2003
  • 资助金额:
    $ 17.97万
  • 项目类别:
PHTHALOCYANINE PHOTODYNAMIC THERAPY MECHANISTIC STUDIES
酞菁光动力治疗机理研究
  • 批准号:
    6665837
  • 财政年份:
    2002
  • 资助金额:
    $ 17.97万
  • 项目类别:
TUMOR PHOTOTHERAPY NEW PHOTODYNAMIC SENSITIZERS
肿瘤光疗新型光动力增敏剂
  • 批准号:
    6665838
  • 财政年份:
    2002
  • 资助金额:
    $ 17.97万
  • 项目类别:
TUMOR PHOTOTHERAPY NEW PHOTODYNAMIC SENSITIZERS
肿瘤光疗新型光动力增敏剂
  • 批准号:
    6486718
  • 财政年份:
    2001
  • 资助金额:
    $ 17.97万
  • 项目类别:
PHTHALOCYANINE PHOTODYNAMIC THERAPY MECHANISTIC STUDIES
酞菁光动力治疗机理研究
  • 批准号:
    6486717
  • 财政年份:
    2001
  • 资助金额:
    $ 17.97万
  • 项目类别:
PHTHALOCYANINE PHOTODYNAMIC THERAPY MECHANISTIC STUDIES
酞菁光动力治疗机理研究
  • 批准号:
    6336787
  • 财政年份:
    2000
  • 资助金额:
    $ 17.97万
  • 项目类别:
SYNTHESIS OF PHTHALOCYANINES FOR TUMOR PHOTOTHERAPY
用于肿瘤光疗的酞菁的合成
  • 批准号:
    6300343
  • 财政年份:
    2000
  • 资助金额:
    $ 17.97万
  • 项目类别:
TUMOR PHOTOTHERAPY NEW PHOTODYNAMIC SENSITIZERS
肿瘤光疗新型光动力增敏剂
  • 批准号:
    6336788
  • 财政年份:
    2000
  • 资助金额:
    $ 17.97万
  • 项目类别:

相似海外基金

RII Track-4:NSF: In-vitro Cytotoxicity Assessment of Synthesized Quantum Dots for Enhanced Cell Imaging
RII Track-4:NSF:用于增强细胞成像的合成量子点的体外细胞毒性评估
  • 批准号:
    2327429
  • 财政年份:
    2024
  • 资助金额:
    $ 17.97万
  • 项目类别:
    Standard Grant
Impact of Obesity on Chemotherapy-Induced Cytotoxicity: Immune Cells and Skeletal Muscle
肥胖对化疗引起的细胞毒性的影响:免疫细胞和骨骼肌
  • 批准号:
    10572695
  • 财政年份:
    2023
  • 资助金额:
    $ 17.97万
  • 项目类别:
Cytotoxicity and function of incomplete proteins
不完整蛋白质的细胞毒性和功能
  • 批准号:
    10570685
  • 财政年份:
    2023
  • 资助金额:
    $ 17.97万
  • 项目类别:
Alpha-Synuclein aberrantly modifies the nanoscale distribution and function of ion channels to promote neuronal cytotoxicity
α-突触核蛋白异常地改变离子通道的纳米级分布和功能以促进神经元细胞毒性
  • 批准号:
    10635208
  • 财政年份:
    2023
  • 资助金额:
    $ 17.97万
  • 项目类别:
SBIR Phase I: Antibody Therapy that Targets Neoantigens in Acute Myeloid Leukemia via the Antibody Dependent Cell-mediated Cytotoxicity Mechanism of Natural Killer Cells
SBIR 第一期:通过抗体依赖性细胞介导的自然杀伤细胞的细胞毒性机制,针对急性髓性白血病新抗原的抗体疗法
  • 批准号:
    2246487
  • 财政年份:
    2023
  • 资助金额:
    $ 17.97万
  • 项目类别:
    Standard Grant
NK Cell Cytotoxicity Against Cryptococcus neoformans in Persons with Advanced HIV and Cryptococcal Meningitis
NK 细胞对晚期 HIV 和隐球菌性脑膜炎患者的新型隐球菌的细胞毒性
  • 批准号:
    10543405
  • 财政年份:
    2022
  • 资助金额:
    $ 17.97万
  • 项目类别:
Antibody dependent cellular cytotoxicity and HIV-1 mother to child transmission
抗体依赖性细胞毒性和 HIV-1 母婴传播
  • 批准号:
    10707299
  • 财政年份:
    2022
  • 资助金额:
    $ 17.97万
  • 项目类别:
Investigating the role of Cdk5 and p35 in natural killer cell cytotoxicity
研究 Cdk5 和 p35 在自然杀伤细胞细胞毒性中的作用
  • 批准号:
    10701749
  • 财政年份:
    2022
  • 资助金额:
    $ 17.97万
  • 项目类别:
Optogenetic interrogation of TDP-43 cytotoxicity
TDP-43 细胞毒性的光遗传学研究
  • 批准号:
    22H02958
  • 财政年份:
    2022
  • 资助金额:
    $ 17.97万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Co-Evolution Mechanisms of Pre-Cancer-Immune Interactions in Shaping Adaptive Cytotoxicity and Myeloid-Derived Suppression
形成适应性细胞毒性和骨髓源性抑制的癌前免疫相互作用的共同进化机制
  • 批准号:
    10518849
  • 财政年份:
    2022
  • 资助金额:
    $ 17.97万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了